[go: up one dir, main page]

MX2016012908A - Conjugados de un resto de interleucina-15 (il-15) y un polimero. - Google Patents

Conjugados de un resto de interleucina-15 (il-15) y un polimero.

Info

Publication number
MX2016012908A
MX2016012908A MX2016012908A MX2016012908A MX2016012908A MX 2016012908 A MX2016012908 A MX 2016012908A MX 2016012908 A MX2016012908 A MX 2016012908A MX 2016012908 A MX2016012908 A MX 2016012908A MX 2016012908 A MX2016012908 A MX 2016012908A
Authority
MX
Mexico
Prior art keywords
conjugates
polymer
interleucine
rest
compositions
Prior art date
Application number
MX2016012908A
Other languages
English (en)
Other versions
MX388865B (es
Inventor
Xiaofeng Liu
Deborah H Charych
Benedict Kirk Peter
Chang Thomas
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MX2016012908A publication Critical patent/MX2016012908A/es
Publication of MX388865B publication Critical patent/MX388865B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan conjugados de un resto de IL-15 y uno o más polímeros hidrosolubles no peptídicos; normalmente, el polímero hidrosoluble no peptídico es poli(etilenglicol) o un derivado de éste; también se proporcionan, entre otras cosas, composiciones que comprenden los conjugados, métodos para preparar los conjugados y métodos para administrar las composiciones a un individuo.
MX2016012908A 2014-04-03 2015-04-01 Conjugados de un resto de interleucina-15 (il-15) y un polimero. MX388865B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461974914P 2014-04-03 2014-04-03
PCT/US2015/023871 WO2015153753A2 (en) 2014-04-03 2015-04-01 Conjugates of an il-15 moiety and a polymer

Publications (2)

Publication Number Publication Date
MX2016012908A true MX2016012908A (es) 2017-01-11
MX388865B MX388865B (es) 2025-03-20

Family

ID=54241432

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016012908A MX388865B (es) 2014-04-03 2015-04-01 Conjugados de un resto de interleucina-15 (il-15) y un polimero.
MX2021015492A MX2021015492A (es) 2014-04-03 2016-09-30 Conjugados de un resto de interleucina-15 (il-15) y un polimero.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021015492A MX2021015492A (es) 2014-04-03 2016-09-30 Conjugados de un resto de interleucina-15 (il-15) y un polimero.

Country Status (12)

Country Link
US (1) US20170035898A1 (es)
EP (2) EP3139947B8 (es)
JP (2) JP6728055B2 (es)
KR (1) KR102432169B1 (es)
CN (1) CN106456716A (es)
AU (3) AU2015240806B2 (es)
CA (1) CA2942571C (es)
ES (1) ES2876433T3 (es)
IL (1) IL248169A0 (es)
MA (1) MA39711A (es)
MX (2) MX388865B (es)
WO (1) WO2015153753A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106913865A (zh) 2013-04-18 2017-07-04 阿尔莫生物科技股份有限公司 使用白细胞介素‑10治疗疾病和病症的方法
AU2014281828B2 (en) 2013-06-17 2019-05-09 Armo Biosciences, Inc. Method for assessing protein identity and stability
AU2014311432A1 (en) 2013-08-30 2016-03-03 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US11413332B2 (en) 2013-11-11 2022-08-16 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
JP2017536098A (ja) 2014-10-14 2017-12-07 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−１５組成物及びその使用
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
HK1248137A1 (zh) 2015-05-28 2018-10-12 阿尔莫生物科技股份有限公司 用於治疗癌症的聚乙二醇化白细胞介素-10
CA2995120A1 (en) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2017062832A1 (en) 2015-10-08 2017-04-13 Nektar Therapeutics Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist
BR112018012262A2 (pt) * 2015-12-21 2018-12-04 Armo Biosciences Inc composições de interleucina-15 e seus usos
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
CN111093688B (zh) 2017-05-15 2025-09-16 尼克塔治疗公司 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
BR112020017016A2 (pt) * 2018-02-26 2020-12-29 Synthorx, Inc. Conjugados da il-15 e usos dos mesmos
CA3119049A1 (en) * 2018-11-09 2020-05-14 Nektar Therapeutics Long-acting interleukin-15 receptor agonist in combination with another pharmacologically active agent
BR112021021481A2 (pt) * 2019-04-26 2021-12-21 Prolynx Llc Conjugados de citocina de liberação lenta
US11248025B2 (en) 2019-06-03 2022-02-15 Medikine, Inc. IL-2alpha receptor subunit binding compounds
MX2022002053A (es) * 2019-08-23 2022-03-17 Synthorx Inc Conjugados de il-15 y sus usos.
JP2024512761A (ja) * 2021-03-29 2024-03-19 オーディー セラピューティクス リミテッド タンパク質－高分子コンジュゲートおよびその使用方法
BR112023027305A2 (pt) 2021-06-23 2024-03-12 Cytune Pharma Variante de interleucina-15, conjugado, proteína de fusão, ácido nucleico, vetor, célula hospedeira e composição farmacêutica
EP4370536A2 (en) * 2021-07-12 2024-05-22 Nektar Therapeutics Polymer engineered forms of interferon-gamma and methods of use
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2025101551A1 (en) * 2023-11-06 2025-05-15 Regents Of The University Of Minnesota Prostate-specific membrane antigen (psma)-binding peptides and method of use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
CN1103815C (zh) * 1993-11-12 2003-03-26 吉里德科学公司 凝血酶突变体
DE69425906T2 (de) 1994-04-06 2001-03-29 Immunex Corp., Seattle Interleukin-15
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US7008624B1 (en) * 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
ATE268609T1 (de) 1998-03-12 2004-06-15 Nektar Therapeutics Al Corp Polyethylenglycolderivate mit benachbarten reaktiven gruppen
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
US7432330B2 (en) * 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
ATE485331T1 (de) 2003-01-06 2010-11-15 Nektar Therapeutics Thiolselektive wasserlösliche polymerderivate
EP1670501A2 (en) * 2003-09-25 2006-06-21 ZymoGenetics, Inc. Methods of treating autoimmune diseases using il-21
US20060057680A1 (en) * 2004-08-11 2006-03-16 Zheng Xin X Mutant interleukin-15 polypeptides
EP1807109A2 (en) 2004-10-05 2007-07-18 Ochsner Clinic Foundation Enhancement of b cell proliferation by il-15
US20060257361A1 (en) * 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
RS53968B1 (sr) 2005-06-16 2015-08-31 Nektar Therapeutics Konjugati koji imaju spojnicu koja može da se razgradi i polimerni reagensi koji su korisni za pripremu takvih konjugata
KR101508621B1 (ko) 2007-02-28 2015-04-07 세리나 쎄라퓨틱스, 인코포레이티드 활성화된 폴리옥사졸린 및 이를 포함하는 조성물
EP2431741B1 (en) * 2008-10-21 2013-08-21 Baxter International Inc Methods for determining active ingredients in pro-drug PEG protein conjugates with releasable PEG reagents (in vitro de-pegylation)
EP3505186B1 (en) * 2010-07-30 2022-01-12 Takeda Pharmaceutical Company Limited Nucleophilic catalysts for oxime linkage
MX388465B (es) * 2010-11-12 2025-03-20 Nektar Therapeutics Conjugados de un resto de interleucina-2 y un polímero.
CN102145178B (zh) * 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
WO2013020079A2 (en) * 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer

Also Published As

Publication number Publication date
EP3139947A2 (en) 2017-03-15
CA2942571C (en) 2023-09-19
JP2017511322A (ja) 2017-04-20
IL248169A0 (en) 2016-11-30
KR20170005793A (ko) 2017-01-16
AU2015240806B2 (en) 2019-09-19
AU2021258008A1 (en) 2021-11-25
EP3139947B1 (en) 2021-05-26
MX388865B (es) 2025-03-20
EP3919071A1 (en) 2021-12-08
MA39711A (fr) 2015-10-08
EP3139947A4 (en) 2018-01-17
KR102432169B1 (ko) 2022-08-11
AU2019283778A1 (en) 2020-01-16
US20170035898A1 (en) 2017-02-09
JP2020114875A (ja) 2020-07-30
WO2015153753A3 (en) 2015-11-26
JP6728055B2 (ja) 2020-07-22
EP3139947B8 (en) 2021-06-30
MX2021015492A (es) 2022-02-22
ES2876433T3 (es) 2021-11-12
CN106456716A (zh) 2017-02-22
CA2942571A1 (en) 2015-10-08
AU2015240806A1 (en) 2016-10-13
WO2015153753A2 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
MX2016012908A (es) Conjugados de un resto de interleucina-15 (il-15) y un polimero.
MX391071B (es) Conjugados de un resto de il-7 y un polímero.
CO2018005381A2 (es) Inhibidores éster de acc y usos de los mismos
CL2017000792A1 (es) Derivados del ácido borónico
NI201700129A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa.
CY1119060T1 (el) Ρυθμιστες ενζυμων μεθυλικης τροποποιησης, συνθεσεις και χρησεις αυτων
MX382791B (es) Conjugados novedosos de glicano y uso de los mismos
MX2017014809A (es) Amidas heterociclicas como inhibidores de cinasa.
MX381160B (es) Agonistas del receptor de apelina y metodos de uso.
AR101905A1 (es) Compuestos bicíclicos
CU24419B1 (es) 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas
CY1120935T1 (el) Νεες συνθεσεις, χρησεις και μεθοδοι για την παρασκευη αυτων
MX2017004906A (es) Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma.
CR20170100A (es) Indazoles sustituidos con bencilo como inhibidores bub1
MX373247B (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina.
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
UY34781A (es) Moduladores de la via del complemento y usos de los mismos
MX2016002517A (es) Copolímeros de poli(furanoato de etileno) y métodos.
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
MX2015009719A (es) Inhibidores benzoquinolona de vmat2.
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
ES2552754T1 (es) Formulaciones de daptomicina y usos de la misma
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
CO2018004573A2 (es) Derivados de fenilo como agonistas del receptor 2 de cannabinoides